FASEB Offers Four Themes at Annual Meeting

The Federation of American Societies for Experimental Biology (FASEB) is holding its 72nd annual meeting this week in Las Vegas. The meeting, one of the world’s largest scientific gatherings, features more than 9,000 scientific papers and nearly 1,000 scientific, technical and educational exhibits. FASEB officials expect more than 20,000 individuals, including 16,000 scientists, to attend the meeting. In addition to sitting in on conventional scientific sessions, attendees have the opp

| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

The Federation of American Societies for Experimental Biology (FASEB) is holding its 72nd annual meeting this week in Las Vegas. The meeting, one of the world’s largest scientific gatherings, features more than 9,000 scientific papers and nearly 1,000 scientific, technical and educational exhibits. FASEB officials expect more than 20,000 individuals, including 16,000 scientists, to attend the meeting.

In addition to sitting in on conventional scientific sessions, attendees have the opportunity to participate in morning-long symposia on four interdisciplinary themes. In arranging these symposia, the Federation is continuing an approach begun in 1981. This year’s themes are cardiovascular disease and ischemic injury, immunopharmacology and immunotoxicity, metabolic regulation and receptors and growth factors.

Another major feature of the week’s activities is a special sympo-, sium on "Immunology in Perspective," which will be discussed by Nobel Laureate Baruj Benacerraf of Harvard Medical School, Elvin A. Kabat of Columbia University, Sir Gustav Nossal of ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies